Mode
Text Size
Log in / Sign up

Case report describes likely first autochthonous Chagas disease case in Missouri blood donor

Case report describes likely first autochthonous Chagas disease case in Missouri blood donor
Photo by Brett Jordan / Unsplash
Key Takeaway
Consider autochthonous Chagas disease in differentials, but recognize this is based on a single case report.

A case report describes a single individual who donated blood in Missouri, United States, and had a positive screening result for Trypanosoma cruzi antibodies. The intervention, comparator, and specific clinical outcomes for the patient were not reported. Based on epidemiologic, clinical, and laboratory data (specifics not provided), the authors concluded the case likely represents the first documented autochthonous case of Chagas disease in Missouri.

No safety, tolerability, or adverse event data were reported for this case. The report did not include details on patient follow-up, treatment, or clinical course.

Key limitations include the nature of the evidence as a single case report, which cannot establish incidence, prevalence, or risk factors. The classification as an autochthonous case is described as 'likely' and is based on unreported specific data points. The funding sources and author conflicts of interest were not reported.

For practice, this report serves as a signal for heightened clinical awareness. It suggests that autochthonous transmission of Trypanosoma cruzi, while rare, may occur in geographic areas not traditionally considered endemic, such as Missouri. However, the evidence remains limited to a single, cautiously interpreted case.

Study Details

EvidenceLevel 5
PublishedFeb 2020
View Original Abstract ↓
In 2017, a person's blood donation in Missouri screened positive for antibodies to Trypanosoma cruzi, the parasite that causes Chagas disease. Based on the epidemiologic, clinical, and laboratory data, the reported case likely represents the first documented autochthonous case of Chagas disease in Missouri.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.